United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$269.15 USD
-3.73 (-1.37%)
Updated May 28, 2024 04:00 PM ET
After-Market: $269.17 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 421 - 440 ( 589 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4:14 Preview: We Believe Consensus is Achievable and Look for Pipeline Update; Reiterate OUTPERFORM and $171 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
January and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
United Therapeutics Plans to Submit sNDA for Remodulin in January 2015; Reiterate OUTPERFORM and $171 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences- Upcoming Events for the Week of Dec 22
Provider: WEDBUSH SECURITIES INC.
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
December and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
November and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Financials Mixed but Long-Term Outlook for Orenitram TiD Better Than We Expected
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
3Q Results Spook at First, But Fundamentals Remain Sound: Reit Buy and $150 PT
Provider: H.C. WAINWRIGHT & CO., INC.
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: We Anticipate Strong Revenues in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
October and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
''117 Patent Upheld; No Generic Remodulin Until Late 2017. Reiterate OUTPERFORM and Increasing PT to $141 for Increased Remodulin Sales.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
September and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L